Abstract
For many vaccine-preventable diseases like influenza, vaccination rates are lower than optimal to achieve community protection. Those at high risk for infection and serious complications are especially advised to be vaccinated to protect themselves. Using influenza as a model, we studied one method of increasing vaccine uptake: informing high-risk patients, identified by a machine learning model, about their risk status. Patients (N=39,717) were evenly randomized to (1) a control condition (exposure only to standard direct mail or patient portal vaccine promotion efforts) or to be told via direct mail, patient portal, and/or SMS that they were (2) at high risk for influenza and its complications if not vaccinated; (3) at high risk according to a review of their medical records; or (4) at high risk according to a computer algorithm analysis of their medical records. Patients in the three treatment conditions were 5.7% more likely to get vaccinated during the 112 days post-intervention (p < .001), and did so 1.4 days earlier (p < .001), on average, than those in the control group. There were no significant differences among risk messages, suggesting that patients are neither especially averse to nor uniquely appreciative of learning their records had been reviewed or that computer algorithms were involved. Similar approaches should be considered for COVID-19 vaccination campaigns.
Competing Interest Statement
A.L. and R.Y. are employed by Medial EarlySign, which designs machine learning-based decision support and risk management tools for health systems. Medial EarlySign employees co-developed the algorithm used to risk-stratify participants but were not involved in the design of this study investigating the effects of disclosing risk status to patients or in the analysis of study data. D.M.W. received grants from Medial EarlySign to support her role in that prior work of co-developing and retrospectively validating the algorithm.
Clinical Trial
NCT04323137
Funding Statement
Research reported in this publication was supported by the National Institute on Aging of the National Institutes of Health under Award Number P30AG034532.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Geisinger IRB approved this study (IRB # 2020-0290) and waived the requirements for consent (under 45 CFR 46.116(c)-(d)) and for HIPAA authorization (under 45 CFR 164.512(i)(2)(ii)). An NIA-convened Data and Safety Monitoring Board also approved and oversaw this study.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Competing Interest Statement: A.L. and R.Y. are employed by Medial EarlySign, which designs machine learning-based decision support and risk management tools for health systems. Medial EarlySign employees co-developed the algorithm used to risk-stratify participants but were not involved in the design of this study investigating the effects of disclosing risk status to patients or in the analysis of study data. D.M.W. received grants from Medial EarlySign to support her role in that prior work of co- developing and retrospectively validating the algorithm.
Data Availability
This study was registered at ClinicalTrials.gov (NCT04323137). Reproducible analysis code for this study is available at https://osf.io/8zpyh/. Data will be available in the same repository upon institutional approval.
